knowledge -WSS

knowledge

author：explore 2025-10-02 22:58:34 - browse：322

Jacob S. Van Naarden (left), Athena Countouriotis( center), and Vlad Coric (right) on stage at the 2023 STAT Summit. — From left, Eli Lilly's Jacob S. Van Naarden, Avenzo's Athena Countouriotis, and Biohaven's Vlad Coric on stage at the 2023 STAT Summit. STAT

What does it feel like to run a biotech startup and then get “the call” — the one from the big pharma CEO who wants to acquire your company for billions of dollars?

At the 2023 STAT Summit on Wednesday, senior biotech writer Adam Feuerstein posed this question to three people very qualified to answer it: Vlad Coric, chairman and CEO of Biohaven, which was acquired by Pfizer in 2022 for $11.6 billion; Jacob Van Naarden, former COO of Loxo Oncology, which was acquired by Eli Lilly (where Van Naarden is now executive vice president) for $8 billion in 2019; and Athena Countouriotis, whose company Turning Point Therapeutics was acquired by BMS for $4 billion in 2022.

“Imagine you’re going through your typical day, and you get a message: Albert Bourla, chairman and CEO of Pfizer, wants to talk at six o’clock tonight,” said Coric, whose company had a successful migraine drug on the market and had just completed an IPO at the time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Why scientists need input from humanists on sensitive research

hotspot

WSS

Supreme Court strikes down use of affirmative action

New air purifier tech could be key to improving indoor air quality

Why scientists need input from humanists on sensitive research

Medical records are filled with copy

UCLA team creates talking throat patch for voice disorders

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

leisure time

knowledge

Wikipedia

Peter Hotez and the public health issue of online harassment

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare details structure of new drug price negotiation program

UCLA team creates talking throat patch for voice disorders

Dobbs anniversary: the lost opportunity of abortion as health care

First U.S. drug developed to treat liver disease MASH is approved

DIEP, the 'gold standard' of breast reconstruction, is under threat

Change Healthcare outage fallout shows need for new oversight

ChatGPT in medicine: STAT answers readers' burning questions

Bright Health sells Medicare Advantage business to Molina

explore

At least 13 dead in Texas as scorching temps continue

Male and female sex labels in research insufficient, scientists say

Medical leaders decry Supreme Court decision on affirmative action

Supreme Court strikes down use of affirmative action

The cancer drug shortage isn’t new — and neither are the solutions

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

hotspot

hotspot

focus

leisure time